Silencing the Suicide Disease: NeuroOne's Bold Move in Southern California

EDEN PRAIRIE, Minn. – September 17, 2026

It is known in medical circles as the "suicide disease." Trigeminal neuralgia, a chronic condition affecting the fifth cranial nerve, delivers sudden, unilateral facial pain so excruciating that patients often compare it to an electric shock or a lightning strike to the jaw. For the estimated 150,000 Americans living with the condition, mundane activities like brushing teeth, chewing, or even feeling a light breeze can trigger agonizing episodes.

Today, NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a strategic distribution agreement that could fundamentally alter how this debilitating condition is treated in one of the nation’s most vital healthcare markets. The medical technology company has secured a regional distribution partnership covering Southern California—including the densely populated Los Angeles metropolitan area—to commercialize its FDA-cleared OneRF Trigeminal Nerve Ablation System.

While the announcement reads like standard corporate expansion, a closer examination reveals a high-stakes convergence of clinical innovation, aggressive small-cap commercialization, and the economic realities of modern neurosurgery.

The Clinical Disruption: Redefining the Surgical Ordeal

To understand the significance of NeuroOne’s device, one must first understand the grueling nature of conventional trigeminal neuralgia treatments. When first-line pharmacotherapy fails—as it does in over half of all patients due to refractory pain or intolerable side effects like cognitive fog—surgical intervention becomes the only viable path.

Historically, the gold standard has been microvascular decompression, an invasive open craniotomy that carries risks of stroke, hearing loss, and cerebrospinal fluid leaks. For elderly or highly comorbid patients, this is often a non-starter. The alternative, percutaneous radiofrequency ablation (RFA), offers rapid relief but subjects the patient to a harrowing operative workflow.

Using legacy single-contact RF systems, a surgeon must repeatedly wake the patient from deep sedation. The patient, in a state of conscious sedation, must verbally confirm whether the electrical stimulation matches their specific pain triggers. If the needle is slightly off, the surgeon must reposition it, re-sedate the patient, and try again. This sleep-wake cycle often repeats three or more times, dragging the procedure out to 90 minutes and subjecting the patient to severe psychological distress and hemodynamic instability.

NeuroOne’s OneRF system aims to eliminate this ordeal. Cleared by the FDA in August 2025, the system utilizes a proprietary multi-contact thin-film probe. Instead of mechanically re-angling a single needle, surgeons can deploy a static array that enables multi-point diagnostic mapping and stimulation across multiple nerve divisions simultaneously.

"The workflow compression is staggering," noted one functional neurosurgeon familiar with the technology. "You are taking a procedure that traditionally requires multiple agonizing wake-up cycles and condensing it into a single, streamlined event. The patient goes to sleep, the multi-contact probe maps the nerve, the ablation is completed with closed-loop temperature monitoring, and the patient wakes up pain-free."

Clinical pilot data released earlier this year underscores this shift. In a cohort of 12 refractory patients across three leading U.S. centers, 100 percent reported immediate freedom from facial pain. Furthermore, the average procedural time plummeted, with the most efficient case completed in just 16 minutes.

The Commercial Gamble: 1099 Networks and Zero Minimums

Despite the clinical elegance of the OneRF system, technological superiority does not automatically translate to commercial success. This is where the Southern California distribution agreement becomes a fascinating case study in medtech strategy.

Southern California is a crown jewel for functional neurosurgery, boasting a dense concentration of high-volume academic medical centers such as UCLA Health, Cedars-Sinai, and Keck Medicine of USC. Penetrating this market is essential for NeuroOne. However, the company is relying on an independent regional distributorship—often referred to as a 1099 network—rather than a direct, in-house sales force.

Dave Rosa, President and Chief Executive Officer of NeuroOne, struck an optimistic tone in today's announcement. “Southern California represents an important market for our OneRF Trigeminal Nerve Ablation System, and this agreement marks another important step in expanding our commercial footprint,” Rosa stated. “We believe this distribution relationship will help bring our technology to more physicians and ultimately help patients suffering from this extremely painful and debilitating condition.”

Yet, forward-looking disclosures in the company's filings reveal the inherent risks of this model. The agreement contains no minimum purchase commitments, guaranteed order sizes, or contractual revenue minimums. The financial upside is entirely dependent on the unnamed distributor’s ability to drive clinical uptake among localized neurosurgeons and pain specialists.

"In the specialized device space, independent reps are highly motivated by commission, but their attention is split across multiple product lines," explained a medtech equity analyst. "Without purchase guarantees, the manufacturer bears the inventory risk. NeuroOne has to prove that its clinical value proposition is strong enough that reps will actively push the OneRF over competing, established systems from giants like Boston Scientific or Stryker."

Financial Realities and the Dual-Track Strategy

NeuroOne’s approach to the trigeminal neuralgia market highlights a broader, dual-track commercial strategy dictated by its balance sheet.

For its core brain and epilepsy portfolio, NeuroOne partnered with orthopedics titan Zimmer Biomet, granting them exclusive global distribution rights in exchange for upfront capital and milestone payments. This provided non-dilutive funding and access to a massive corporate sales infrastructure. However, for the OneRF Trigeminal Nerve Ablation System, NeuroOne opted to retain commercial rights, betting that it could capture higher margins by building its own targeted networks.

The financial tightrope is evident in the company's latest fiscal disclosures. For the quarter ending June 30, 2026, NeuroOne reported a record 59.9 percent product gross margin and $2.0 million in product revenue, marking a 16 percent year-over-year increase. Yet, operating expenses outpaced revenue, resulting in a $2.0 million net loss for the quarter.

With cash and cash equivalents sitting at $2.0 million as of mid-2026, the company is operating with a highly constrained runway, buffered primarily by an At-The-Market (ATM) equity facility. Rapid sales conversion in high-value markets like Los Angeles is not just a strategic goal; it is a financial imperative. The company needs the high-margin consumable probe kits to generate immediate cash flow without triggering massive direct sales expenses.

The Economic Value Proposition for Providers

Fortunately for NeuroOne, the economic environment for percutaneous radiofrequency rhizotomy is highly favorable. The procedure operates within an established reimbursement framework across both Medicare and commercial payers.

Under CPT code 61790, the procedure yields robust physician professional fees. In the Southern California locality, geographic adjustments push the operating surgeon's reimbursement to approximately $880 to $1,050 under Medicare, with private commercial payers frequently reimbursing between $1,150 and $1,450. In the hospital outpatient setting, the facility fee easily eclipses $2,000 per encounter.

Beyond direct reimbursement, the OneRF system offers hospitals a compelling capital synergy. The trigeminal ablation probe utilizes the exact same OneRF generator console that many hospitals have already acquired for epilepsy brain mapping. This shared architecture means that administrators do not need to navigate complex capital acquisition review cycles—which can easily delay purchases of $40,000 to $65,000 standalone RF generators. Instead, the distributor simply sells the single-use disposable OneRF Trigeminal Nerve Ablation Kits directly to the surgical department.

Furthermore, the dramatic reduction in operative time presents a massive efficiency gain. Operating room time is typically valued between $35 and $80 per minute. By compressing a 75-minute procedure into a 30-minute window, hospitals can double their daily throughput for complex cranial nerve interventions while simultaneously mitigating the risks of extended conscious sedation.

As NeuroOne moves to execute this Southern California rollout, the industry will be watching closely. The technology has already demonstrated its capacity to silence one of medicine's most agonizing conditions. The question now is whether a lean, specialized commercial strategy can successfully navigate the complexities of the American healthcare market and deliver the financial stability required to fuel the next era of neurosurgical innovation.